中泰证券（600918）发布研报称，维持和铂医药-B(02142)"买入"评级。基于HBM7020、HBM4003对外 授权的首付款、近期付款及风险调整里程碑收入带来的增量，预计公司2025~2027年实现营业总收入 14.00、15.94、14.85亿元(前值13.42、9.74、10.26亿元)，实现归母净利润6.65、7.68、7.40亿元(前值 6.21、3.07、4.32亿元)。 中泰证券主要观点如下： 事件 2026年2月23日，和铂医药(02142)宣布与Solstice Oncology(一家由多个头部风险投资机构联合创立的临 床阶段生物技术公司)达成授权协议及股权合作，授予对方一款临床阶段候选产品HBM4003(CTLA-4抗 体)在大中华区以外地区的独家开发及商业化权益。根据协议，和铂医药将获得总价值逾1.05亿美元的 前期对价，包括现金形式的5000万美元首付款、500万美元近期付款以及价值逾5000万美元的Solstice Oncology股权。此外，基于未来特定里程碑事件的达成，和铂医药还有资格进一步获得最高约11亿美元 的开发、监管及商业里程碑付款，以及基于大中华区以外地区净销售额 ...

Marker Therapeutics (NasdaqCM:MRKR) FY Conference February 25, 2026 08:00 AM ET Company ParticipantsAnthony - AssociateJuan Vera - President and CEOAnthonyGood morning, everyone, and thanks so much for joining us. I'm Anthony, an associate here at Oppenheimer, and it is my pleasure to introduce Marker Therapeutics. Marker is an immuno-oncology company focused on developing T-cell therapies using its multi-antigen recognizing or MAR-T platform. The lead program is MT-601, and it's being studied in relapse ly ...

智通财经APP获悉，致力于开发活体生物药物以激发免疫反应的临床阶段癌症生物技术公司 Salspera(TKVA.US)，周一披露了其美股首次公开募股(IPO)条款。 Salspera旨在开发一类全新的免疫疗法用于治疗实体瘤，该公司将其命名为"活体生物药"，即经过基因 改造、能够在肿瘤微环境内表达特定抗肿瘤因子的生物制剂。 其先导项目Saltikva是一种经过减毒改造的鼠伤寒沙门氏菌菌株，无毒且可口服给药。该菌株经工程化 设计，可表达人白细胞介素-2基因(即Salmonella-IL2)，这可能有助于增加肿瘤微环境及外周血中NK细 胞和CD8+细胞毒性T细胞的数量。公司目前主要针对胰腺癌，并已完成一项针对IV期转移性胰腺癌患 者的II期试验。 Salspera成立于2017年，计划在纳斯达克上市，股票代码为TKVA。Kingswood资本市场担任该交易的独 家账簿管理人。 这家总部位于马萨诸塞州剑桥市的公司计划通过发行570万股股票(发行价区间为每股14至16美元)筹集 8500万美元资金。 ...

Company Performance & Financials - BeOne Medicines delivered significant product revenue growth, with a 43% increase in the first three quarters of 2025 [17] - BRUKINSA rapidly became the global BTKi leader, showing a 51% increase in approved indications [20] - The company's pipeline achieved proof of concept for 6 assets across 4 modalities and brought 5 new molecular entities (NMEs) to the clinic in 2025 [22] CLL Treatment Landscape & BRUKINSA - BRUKINSA demonstrates progression-free survival (PFS) superiority to ibrutinib, with a hazard ratio (HR) of 069 (95% CI: 055, 087), p-value: 00014 [53] - Recent competitor efficacy data does not indicate a change to the CLL treatment landscape, with Pirtobrutinib showing a HR of 0845 (95% CI: 0566-1262), p-value: 04102 [60] - In the ALPINE trial, Zanubrutinib had a lower rate of adverse events (AEs) leading to treatment discontinuation at 77% compared to ibrutinib at 130% [65] ZS (Zanubrutinib + Sonrotoclax) Regimen - ZS (Zanubrutinib + sonrotoclax) is poised to be a fixed duration regimen with a 91% undetectable minimal residual disease (uMRD) rate [74] - ZS showed a 100% 36-month PFS rate (at 30 months) [74] - The company is initiating a Phase 3 trial of ZS vs AV in 1L CLL in H1 2026 [101] Pipeline & Future Milestones - The company has approximately 8-10 new molecular entities (NMEs) per year in its pipeline [105] - BeOne is the only company with best-in-class foundational medicines across the three key mechanisms of action (MOAs) in CLL [99] - The company anticipates several milestones in H1 and H2 2026, including Phase 3 data for BRUKINSA+R vs BR in 1L MCL and a potential R/R MCL U S approval for Sonro [101]

Group 1: Leadership and Strategic Developments - Oncolytics Biotech Inc. has strengthened its leadership by appointing Dr. Eileen O'Reilly, Dr. Neil Segal, and Dr. Van Morris to its Gastrointestinal Tumor Scientific Advisory Board, enhancing clinical and strategic oversight as the company advances pelareorep toward registration-enabling trials in pancreatic, colorectal, and anal cancers [2] - The expanded advisory board is expected to sharpen the late-stage development strategy for a GI-focused immunotherapy platform, which targets large addressable markets [2] Group 2: Clinical and Translational Momentum - Recent data from trials in second-line KRAS-mutant, microsatellite-stable metastatic colorectal cancer showed a 33% objective response rate, significantly higher than the historical rate of 6-11% [3] - The trials also indicated more than double the progression-free and overall survival compared to standard therapy, highlighting the potential effectiveness of pelareorep [3] - Increased KRAS-specific T-cell responses were reported in translational analyses, reinforcing the mechanistic differentiation of pelareorep [3] Group 3: Company Focus and Technology - Oncolytics Biotech Inc. is focused on developing pelareorep, an immune-oncolytic virus platform that targets solid tumors and hematologic malignancies [4] - The technology leverages tumor-selective viral replication to stimulate both innate and adaptive anti-cancer immune responses [4]

Summary of Candel Therapeutics R&D Day Conference Call Company Overview - **Company**: Candel Therapeutics (NasdaqGM:CADL) - **Focus**: Development of viral immunotherapies for difficult-to-treat solid tumors, specifically CAN-2409 and CAN-3110 [2][5] Key Programs and Clinical Trials CAN-2409 - **Description**: Off-the-shelf immunotherapy targeting pan-solid tumors, particularly localized prostate cancer. - **Clinical Trial**: Phase 3 trial with 745 patients, met primary endpoint of disease-free survival, showing a 30% risk reduction in disease recurrence [2][63]. - **FDA Designations**: Received Fast Track and RMAT designations, indicating significant potential for breakthrough therapy [3]. - **Results**: - 38% reduction in prostate cancer recurrence risk [65]. - 80.4% of patients free of prostate cancer at two years post-radiotherapy [67]. - **Administration**: Involves three courses of intraprostatic injections combined with standard care radiotherapy [62]. CAN-3110 - **Description**: A replication-competent herpes simplex virus designed for oncolytic therapy, targeting recurrent high-grade glioma. - **Results**: Promising data published in high-impact journals, indicating potential for other tumors expressing Nestin [6]. Financial Position - **Cash Reserves**: $87 million as of September 2025, with a runway into Q1 2027 [6]. - **Loan Facility**: Entered a term loan facility with Trinity Capital for up to $130 million [7]. Industry Insights and Future Directions - **Immunotherapy Trends**: Discussion on the importance of understanding immune responses and the need for longitudinal studies to improve patient selection for therapies [19][20]. - **Combination Therapies**: Emphasis on the potential of combining immunotherapies with standard treatments and the need for innovative trial designs to test combinations effectively [40][41]. - **Emerging Technologies**: Interest in RNA vaccines and epigenetic pathways as future avenues for enhancing immunotherapy efficacy [34][36]. Challenges and Considerations - **Clinical Trial Design**: Need for smaller, more adaptive trials to better understand the mechanisms of action and patient responses [44][50]. - **Data Integration**: Importance of integrating computational biology and big data analytics to uncover hidden signals in tumor responses [51][54]. Conclusion - Candel Therapeutics is positioned to address significant unmet needs in cancer treatment, particularly with its lead asset CAN-2409, which has shown promising clinical results. The company is focused on innovative trial designs and combination therapies to enhance treatment outcomes for patients with solid tumors [58][60].

AIM ImmunoTech Conference Summary Company Overview - **Company**: AIM ImmunoTech (NYSEAM:AIM) - **Lead Asset**: Ampligen, a drug with potential in immuno-oncology, effective as both a monotherapy and a synergistic enhancer to checkpoint inhibitors across various solid tumors [8][12] Core Points and Arguments - **Ampligen's Potential**: - Demonstrated strong impact in improving response rates for patients who are refractory to checkpoint inhibitors [8] - Alters tumor microenvironment to enhance visibility to immune system, transforming "cold tumors" into "hot tumors" [11][12] - **Strategic Focus on Pancreatic Cancer**: - AIM has prioritized pancreatic cancer as its lead indication due to the high unmet medical need and potential for significant impact on patient survival [13][15] - The company aims to leverage its data showing Ampligen's ability to extend overall survival in pancreatic cancer, both as a monotherapy and in combination with AstraZeneca's Durvalumab [15][19] - Orphan drug designations received in the U.S. and Europe provide market exclusivity, enhancing the business opportunity [16][17] - **Market Context**: - Over 500,000 deaths annually from pancreatic cancer, with a low survival rate, highlighting the critical need for effective treatments [19] - The oncology sector is where significant biotech deals occur, with potential for billion-dollar partnerships [14][28] - **Clinical and Regulatory Strategy**: - AIM is working towards initiating a Phase 3 trial in pancreatic cancer, ideally in conjunction with checkpoint inhibitors [24][25] - The company has treated 57 subjects, demonstrating the ability to extend overall survival beyond standard care [25] - **Upcoming Milestones**: - Anticipation of a positive year-end report, which is expected to be a significant inflection point for the company [28] - Plans to find a big pharma partner to support the Phase 3 trial and capitalize on the research and development efforts [26][28] Other Important Content - **Collaborations**: - Successful collaborations with Merck and AstraZeneca have been crucial for advancing Ampligen's development [30] - Data from independent research institutions supports the efficacy of Ampligen in various cancers, not limited to pancreatic cancer [29][30] - **Quality of Life Considerations**: - Ampligen is noted for improving the quality of life for patients undergoing treatment, which is particularly important for those facing severe malignancies [15][16] - **Company's Position**: - AIM is a small biotech company with limited resources but is making significant strides in oncology research [31] - The CEO expressed gratitude towards collaborators, investors, and the research community for their support [39][40] This summary encapsulates the key insights from the AIM ImmunoTech conference, focusing on the company's strategic direction, clinical developments, and market opportunities in the context of pancreatic cancer and broader oncology applications.

香港聯合交易所有限公司及證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不就因本申請版本全部或任何部分內容而產生或依賴該等內容而引致 的任何損失承擔任何責任。 Hanx Biopharmaceuticals (Wuhan) Co., Ltd. 翰 思 艾 泰 生 物 醫 藥 科 技（ 武 漢 ）股 份 有 限 公 司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）╱證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本。本申請版本內所載資訊並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即 代表 閣下知悉、接納並向本公司、其獨家保薦人、獨家整體協調人、顧問或包銷團成員表示同意： 於本公司招股章程根據香港法例第32章公司（清盤及雜項條文）條例送呈香港公司註冊處處長登記前，不 會向香港公眾人士提出要約或邀請。倘在適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依 據於香港公司註冊處處長註冊的本公司招股章程作出投資決定。該 ...

香港聯合交易所有限公司及證券及期貨事務監察委員會對本聆訊後資料集的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不就因本聆訊後資料集全部或任何部分內容而產生或依賴該等內 容而引致的任何損失承擔任何責任。 Hanx Biopharmaceuticals (Wuhan) Co., Ltd. 翰 思 艾 泰 生 物 醫 藥 科 技（ 武 漢 ）股 份 有 限 公 司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的聆訊後資料集 警告 本聆訊後資料集乃根據香港聯合交易所有限公司（「聯交所」）╱證券及期貨事務監察委員會（「證監會」）的 要求而刊發，僅用作提供資訊予香港公眾人士。 本聆訊後資料集為草擬本。本聆訊後資料集內所載資訊並不完整，亦可能會作出重大變動。 閣下閱覽本 文件，即代表 閣下知悉、接納並向本公司、其獨家保薦人、獨家整體協調人、顧問或包銷團成員表示同 意： 於本公司招股章程根據香港法例第32章公司（清盤及雜項條文）條例送呈香港公司註冊處處長登記前，不 會向香港公眾人士提出要約或邀請。倘在適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依 據於香港公司註冊處處長註冊的本公 ...

Core Viewpoint - Kewang Pharmaceutical Group has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor. The company aims to develop next-generation cancer therapies globally, focusing on its core product ES102, an advanced six-valent OX40 agonist currently in clinical development [1][6]. Company Overview - Kewang Pharmaceutical, established in 2017, is a clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies by understanding the tumor microenvironment (TME) [6]. - The core product, ES102, is designed to treat cancer patients who respond poorly to immune checkpoint inhibitors (ICIs) and has shown controllable safety and anti-tumor activity in clinical trials [6][7]. Clinical Development - Since acquiring ES102 from Inhibrx in 2018, Kewang has completed two Phase 1 clinical trials in China for advanced solid tumor patients and has initiated a Phase 2 trial combining ES102 with a PD-1 inhibitor for advanced NSCLC patients [7]. - The company has a differentiated pipeline with five major assets, three of which are in clinical stages, targeting unmet medical needs in major tumor types [7]. Research and Development Capabilities - Kewang has established a comprehensive drug development engine, equipped with proprietary technologies covering the entire R&D cycle from drug discovery to clinical development [8]. - The company has developed multiple proprietary antibody discovery platforms, which are crucial for accelerating drug discovery and improving cost-effectiveness [8]. Strategic Partnerships - Kewang has formed a strategic partnership with AstraZeneca to collaborate on a new bispecific macrophage connector project, potentially earning over $1.7 billion in milestone payments [9]. - The company has also partnered with Partex N.V. to develop a platform for designing new therapeutic antibodies, leveraging AI technology [8]. Financial Overview - For the year 2024, Kewang is projected to generate revenue of RMB 106.566 million from its collaboration with AstraZeneca [10]. - The company reported a loss of RMB 729.508 million for the year 2023, with a significant reduction in losses expected in subsequent periods [10].